Shares of Erasca Inc. (ERAS) touched a 52-week high of $24.28 during intraday trading yesterday, as the company gears up for clinical data readouts of its lead drug candidate ERAS-0015.
ERAS-0015 is a pan-RAS molecular glue designed to target RAS proteins in their active (GTP-bound) state. By doing so, it can block the signaling pathways driven by both mutant and normal RAS, potentially stopping cancer cell growth. The RAS pathway is implicated in multiple cancers.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com